Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)
Boston Scientific (BSX) posted quarterly Current Deferred Revenue of $258.0 million for Q3 2020, up 2.79% on a QoQ basis from $251.0 million in Q2 2020.
Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020) Analysis & Trends
Boston Scientific has reported Current Deferred Revenue for 2 years, with the latest figure at $258.0 million in Q3 2020.
- Current Deferred Revenue for Q3 2020 came in at $258.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2020 was $258.0 million (changed N/A YoY), and the FY2019 annual result was $257.0 million, changed N/A from the prior year.
- Current Deferred Revenue grew to $258.0 million in Q3 2020, from $251.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $258.0 million in Q3 2020 and troughed at $251.0 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn |
| 10 | Zimmer Biomet Holdings | 19.23 Bn | 18.82 Bn | 1.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 147.00 Mn |
| Jun 30, 2020 | 143.00 Mn |
| Mar 31, 2020 | 141.00 Mn |
| Dec 31, 2019 | 257.00 Mn |